Evidence-based treatment approach to autism spectrum disorders

Pediatric Annals

Volumn 40, Issue 11, 2011, Pages 569-574

  Munshi, Kaizad R ^a   Gonzalez Heydrich, Joseph ^a   Augenste, Tara ^a   D'Angelo, Eugene J ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLONIDINE; CYCLOSERINE; HALOPERIDOL; MEMANTINE; METHYLPHENIDATE; OLANZAPINE; OXYTOCIN; PLACEBO; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TIANEPTINE; VALPROIC ACID; NEUROLEPTIC AGENT;

AGGRESSION; ANXIETY DISORDER; ARTICLE; AUTISM; BEHAVIOR THERAPY; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL PROTOCOL; COGNITIVE THERAPY; COMMUNICATION DISORDER; COMORBIDITY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERACTIVITY; IRRITABILITY; LANGUAGE DISABILITY; METABOLIC SYNDROME X; MOOD DISORDER; PARENT COUNSELING; PEER REVIEW; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REINFORCEMENT; SIDE EFFECT; SLEEP DISORDER; SOCIAL DISABILITY; STEREOTYPY; TREATMENT DURATION; WEIGHT GAIN; CHILD; MULTIMODALITY CANCER THERAPY; REVIEW; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; COMORBIDITY; EVIDENCE-BASED MEDICINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84855363732     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/00904481-20111007-08     Document Type: Article

References (46)

1. King BH, Hollander MD, Sikich L, et al; STAART Psychopharmacology Network. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior. Arch Gen Psychiatry. 2009;66(6):583-590.
2. Williams K, Wheeler DM, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2010 Aug 4;(8):CD004677.
3. Foxx RM. Applied behavior analysis treatment of autism: The state of the art. Child Adolesc Psychiatr Clin N Am. 2008;17(4):821-834.
4. Virués-Ortega J. Applied behavior analytic intervention for autism in early childhood: Meta-analysis, meta-regression and doseresponse meta-analysis of multiple outcomes. Clin Psychol Review. 2010;30(4):387-399.
5. Ospina MB, Seida JK, Clark B, et al. Behavioural and developmental interventions for Autism Spectrum Disorder: A clinical systematic review. PLoS ONE. 3(11):e3755.
6. McCracken JT, McGough J, Shah B, et al.; Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314-321.
7. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: Longerterm benefits and blinded discontinuation after 6 months. Am J Psychiatry. 2005;162(7):1361-1369.
8. McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry. 2005;162(6):1142-1148.
9. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5):e634-e641.
10. Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2007;37(2):367-373.
11. Troost PW, Lahuis BE, Steenhuis M, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry. 2005;44(11):1137-1144.
12. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: Randomized, placebo- controlled, double-blind study. J Child Neurol. 2006;21(6):450-455.
13. Miral S, Gencer O, Inal-Emiroglu FN, Baykara B, Baykara A, Dirik E. Risperidone versus haloperidol in children and adolescents with AD. Eur Child Adolesc Psychiatry. 2008;17(1):1-8.
14. Canitano R, Scandurra V. Psychopharmacology in autism: An update. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):18-28.
15. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110-1119.
16. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, Carson WH, Findling RL. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533-1540.
17. Stigler KA, McDougle CJ. Pharmacotherapy of irritability in pervasive developmental disorders. Child Adolesc Psychiatr Clin N Am. 2008;17(4):739-752.
18. Remington G, Sloman L, Konstantareas M, Parker K, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: A double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol. 2001;21(4):440-444.
19. Gencer O, Inal-Emiroglu FN, Miral S, Baykara B, Baykara A, Dirik E. Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. Eur Child Adolesc Psychiatry. 2008;17(4):217-225.
20. Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2006;16(5):541-548.
21. Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M. Naltrexone in autistic children: Behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry. 1993;32(6):1283-1291.
22. Willemsen-Swinkels SH, Buitelaar JK, Weijnen FG, van Engeland H. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res. 1995;58(3):203-215.
23. Willemsen-Swinkels SH, Buitelaar JK, van Engeland H. The effects of chronic naltrexone treatment in young autistic children: A double-blind placebo-controlled study. Biol Psychiatry. 1996;39(12):1023-1031.
24. Ghaziuddin M. Mental Health Aspects of Autism and Asperger Syndrome. London & Philadelphia: Jessica Kingsley Publishers; 2005.
25. Sofronoff K, Attwood T, Hinton S. A randomised controlled trial of a CBT intervention for anxiety in children with Asperger syndrome. J Child Psychol Psychiatry. 2005;46(11):1152-1160.
26. Posey DJ, Aman MG, McCracken JT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry. 2007;61(4):538-544.
27. Ghuman JK, Aman MG, Lecavalier L, et al. Randomized, placebo-controlled, crossover study of methylphenidate for attentiondeficit/ hyperactivity disorder symptoms in preschoolers with developmental disorders. J Child Adolesc Psychopharmacol. 2009;19(4):329-339.
28. Arnold LE, Aman MG, Cook AM, Witwer AN, Hall KL, Thompson S, Ramadan Y. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry. 2006;45(10):1196-1205.
29. Jaselskis CA, Cook EH, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol. 1992;12(5):322-327.
30. Lainhart J, Folstein S. Affective disorders in people with autism: a review of published cases. J Autism Dev Disord. 1994;24(5):587-601.
31. Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol. 2006;16(5):575-587.
32. Ooi Y, Lam C, Sung M, et al. Effects of cognitive- behavioral therapy on anxiety for children with high-functioning autistic spectrum disorders. Singapore Med J. 2008;49(3):215-220.
33. Chalfant A, Rapee R, Carroll L. Treating anxiety disorders in children with high functioning autism spectrum disorders: a controlled trial. J Autism Dev Disord. 2007;37(10):1842-1857.
34. Wood JJ, Drahota A, Sze K, Har K, Chiu A, Langer DA. Cognitive behavioral therapy for anxiety in children with autism spectrum disorders: A randomized, controlled trial. J Child Psychol Psychiatry. 2009;50(3):224-234.
35. Beaumont R, Sofronoff K. A multi-component social skills intervention for children with Asperger syndrome: the junior detective training program. J Child Psychol Psychiatry. 2008;49(7):743-753.
36. Sze K, Wood J. Cognitive behavioural treatment of comorbid anxiety disorders and social difficulties in children with high-functioning autism: A case report. J Contemp Psychotherapy. 2007;37:133-143.
37. Malow BA. Sleep disorders, epilepsy, and autism. Ment Retard Dev Disabil Res Rev. 2004;10(2):122-125.
38. Stewart ME, Barnard L, Pearson J, Hasan R, O'Brien G. Presentation of depression in autism and Asperger syndrome: a review. Autism. 2006;10(1):103-116.
39. Aman MG, McDougle CJ, Scahill L, et al; Research Units on Pediatric Psychopharmacology Autism Network. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2009;48(12):1143-1154.
40. Frazier TW, Youngstrom EA, Haycook T, et al. Effectiveness of medication combined with intensive behavioral intervention for reducing aggression in youth with autism spectrum disorder. J Child Adolesc Psychopharmacol. 2010;20(3):167-177.
41. King BH, Wright DM, Handen BL, et al. Double- blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40(6):658-665.
42. Neiderhofer H, Staffen W, Mair A. Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder. Hum Psychopharmachol. 2003;18(5):389-393.
43. Wink L, Erickson CA, McDougle CJ. Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Curr Treat Options Neurol. 2010;12(6):529-538.
44. Posey DJ, Stigler KA, Erikson CA, et al. A double-blind placebo-controlled study of Dcycloserine in children with autistic disorder [abstract P3.53:83]. Presented at the 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry Scientific Proceedings, Chicago, IL; Oct. 29-Nov. 1, 2008. As cited in Wink LK, Erickson CA, McDougle CJ. Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Curr Treat Options Neurol. 2010;12(6):529-538.
45. Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl). 2007;191(1):141-147.
46. Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L, Anagnostou E, Wasserman S. Oxytocin increases retention of social cognition in autism. Biol Psychiatry. 2007;61(4):498-503.